736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)Chrisann Kyi, Alexander I. Spira, David P. Carbone et al.|Annals of Oncology|2022Cited by 5